SK Pharmteco Launches SKyvec™ Platform to Streamline Gene Therapy Development
Event summary
- SK pharmteco launched SKyvec™, a proprietary multimodal viral vector platform on June 23, 2026.
- The platform integrates development capabilities with global manufacturing expertise across North America and Europe.
- SKyvec™ offers three core modalities: AAV, Lenti, and Adeno, each designed for high-yield, scalable production.
- The platform aims to address industry bottlenecks with processing enhancements delivering 5x to 6x productivity gains.
The big picture
SK pharmteco's SKyvec™ platform launch addresses critical scalability and cost challenges in the gene therapy sector. As demand for viral vectors grows, the platform's high-yield manufacturing capabilities position it as a key player in accelerating clinical timelines. The integration of development and global manufacturing expertise underscores a strategic shift toward end-to-end solutions in the biopharmaceutical CDMO space.
What we're watching
- Adoption Pace
- How quickly biopharmaceutical companies will integrate SKyvec™ into their gene therapy development pipelines.
- Competitive Response
- Whether existing CDMOs will introduce competing platforms to match SKyvec™'s capabilities.
- Regulatory Alignment
- The extent to which SKyvec™'s regulatory-ready solutions will streamline approval processes for gene therapy programs.
Related topics